CN101810569A - 一种恩诺沙星注射液及其制备方法 - Google Patents
一种恩诺沙星注射液及其制备方法 Download PDFInfo
- Publication number
- CN101810569A CN101810569A CN201010179923A CN201010179923A CN101810569A CN 101810569 A CN101810569 A CN 101810569A CN 201010179923 A CN201010179923 A CN 201010179923A CN 201010179923 A CN201010179923 A CN 201010179923A CN 101810569 A CN101810569 A CN 101810569A
- Authority
- CN
- China
- Prior art keywords
- enrofloxacin
- injection
- preparation
- enrofloxacin injection
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 79
- 238000002347 injection Methods 0.000 title claims abstract description 66
- 239000007924 injection Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims description 14
- 239000007788 liquid Substances 0.000 title abstract description 12
- 230000007935 neutral effect Effects 0.000 claims abstract description 21
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 19
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 16
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 12
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical group [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 8
- 235000019345 sodium thiosulphate Nutrition 0.000 claims description 8
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims description 6
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 230000007794 irritation Effects 0.000 abstract 2
- 239000002738 chelating agent Substances 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 229960001484 edetic acid Drugs 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
对照组(不给药) | 实施例1 | 实施例2 | 实施例3 | 实施例4 | |
感染率 | 100% | 100% | 100% | 100% | 100% |
对照组(不给药) | 实施例1 | 实施例2 | 实施例3 | 实施例4 | |
死亡率 | 94% | 2% | 6% | 11% | 3% |
治愈率 | - | 98% | 93% | 89% | 97% |
Claims (10)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010179923XA CN101810569B (zh) | 2010-05-22 | 2010-05-22 | 一种恩诺沙星注射液及其制备方法 |
AU2011101749A AU2011101749A4 (en) | 2010-05-22 | 2011-05-20 | Injection of enrofloxacin and producing method thereof |
AU2011257785A AU2011257785A1 (en) | 2010-05-22 | 2011-05-20 | Injection of enrofloxacin and producing method thereof |
PCT/CN2011/074426 WO2011147280A1 (zh) | 2010-05-22 | 2011-05-20 | 一种恩诺沙星注射液及其制备方法 |
KR1020127021886A KR20130080422A (ko) | 2010-05-22 | 2011-05-20 | 엔로플록사신의 주사제 및 그의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010179923XA CN101810569B (zh) | 2010-05-22 | 2010-05-22 | 一种恩诺沙星注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101810569A true CN101810569A (zh) | 2010-08-25 |
CN101810569B CN101810569B (zh) | 2011-09-21 |
Family
ID=42618033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010179923XA Expired - Fee Related CN101810569B (zh) | 2010-05-22 | 2010-05-22 | 一种恩诺沙星注射液及其制备方法 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20130080422A (zh) |
CN (1) | CN101810569B (zh) |
AU (2) | AU2011101749A4 (zh) |
WO (1) | WO2011147280A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011147280A1 (zh) * | 2010-05-22 | 2011-12-01 | 鼎正动物药业(天津)有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN102772359A (zh) * | 2012-08-02 | 2012-11-14 | 挑战(天津)动物药业有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN104586757A (zh) * | 2015-01-08 | 2015-05-06 | 邳州正康生物技术有限公司 | 一种兽用恩诺沙星注射液及其制备方法 |
CN104606671A (zh) * | 2014-12-30 | 2015-05-13 | 天津市中升挑战生物科技有限公司 | 一种复方溶菌酶恩诺沙星注射制剂 |
CN107095848A (zh) * | 2017-07-01 | 2017-08-29 | 山东中牧兽药有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN111973553A (zh) * | 2020-09-03 | 2020-11-24 | 江西省科达动物药业有限公司 | 一种高稳定性的恩诺沙星注射液及其制备方法 |
CN112174888A (zh) * | 2019-07-04 | 2021-01-05 | 天津市中升挑战生物科技有限公司 | 一种恩诺沙星单晶型物及其制备方法 |
CN117530922A (zh) * | 2024-01-09 | 2024-02-09 | 中国农业大学 | 一种兽用高稳定性复方注射液及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1177300A (zh) * | 1995-01-13 | 1998-03-25 | 拜尔公司 | 恩氟沙星注射液或输液 |
CN1288725A (zh) * | 2000-06-30 | 2001-03-28 | 程广亚 | 畜禽注射液及其系列产品的制备方法 |
EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
CN101301291A (zh) * | 2008-04-11 | 2008-11-12 | 天津生机集团股份有限公司 | 兽用复方恩诺沙星注射液及其制备方法 |
CN101347432A (zh) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | 一种畜禽用长效恩诺沙星注射液及其制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006010642A1 (de) * | 2006-03-08 | 2007-09-27 | Bayer Healthcare Aktiengesellschaft | Arzneimittelformulierungen, enthaltend Fluorchinolone |
CN101810569B (zh) * | 2010-05-22 | 2011-09-21 | 鼎正动物药业(天津)有限公司 | 一种恩诺沙星注射液及其制备方法 |
-
2010
- 2010-05-22 CN CN201010179923XA patent/CN101810569B/zh not_active Expired - Fee Related
-
2011
- 2011-05-20 AU AU2011101749A patent/AU2011101749A4/en not_active Ceased
- 2011-05-20 KR KR1020127021886A patent/KR20130080422A/ko not_active Application Discontinuation
- 2011-05-20 WO PCT/CN2011/074426 patent/WO2011147280A1/zh active Application Filing
- 2011-05-20 AU AU2011257785A patent/AU2011257785A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1177300A (zh) * | 1995-01-13 | 1998-03-25 | 拜尔公司 | 恩氟沙星注射液或输液 |
CN1288725A (zh) * | 2000-06-30 | 2001-03-28 | 程广亚 | 畜禽注射液及其系列产品的制备方法 |
EP1902706A1 (en) * | 2006-09-25 | 2008-03-26 | Divasa-Farmavic, S.A. | Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses |
CN101301291A (zh) * | 2008-04-11 | 2008-11-12 | 天津生机集团股份有限公司 | 兽用复方恩诺沙星注射液及其制备方法 |
CN101347432A (zh) * | 2008-09-05 | 2009-01-21 | 郑州后羿制药有限公司 | 一种畜禽用长效恩诺沙星注射液及其制备方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011147280A1 (zh) * | 2010-05-22 | 2011-12-01 | 鼎正动物药业(天津)有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN102772359A (zh) * | 2012-08-02 | 2012-11-14 | 挑战(天津)动物药业有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN104606671A (zh) * | 2014-12-30 | 2015-05-13 | 天津市中升挑战生物科技有限公司 | 一种复方溶菌酶恩诺沙星注射制剂 |
CN104586757A (zh) * | 2015-01-08 | 2015-05-06 | 邳州正康生物技术有限公司 | 一种兽用恩诺沙星注射液及其制备方法 |
CN107095848A (zh) * | 2017-07-01 | 2017-08-29 | 山东中牧兽药有限公司 | 一种恩诺沙星注射液及其制备方法 |
CN112174888A (zh) * | 2019-07-04 | 2021-01-05 | 天津市中升挑战生物科技有限公司 | 一种恩诺沙星单晶型物及其制备方法 |
CN111973553A (zh) * | 2020-09-03 | 2020-11-24 | 江西省科达动物药业有限公司 | 一种高稳定性的恩诺沙星注射液及其制备方法 |
CN117530922A (zh) * | 2024-01-09 | 2024-02-09 | 中国农业大学 | 一种兽用高稳定性复方注射液及其制备方法和应用 |
CN117530922B (zh) * | 2024-01-09 | 2024-04-26 | 中国农业大学 | 一种兽用高稳定性复方注射液及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
KR20130080422A (ko) | 2013-07-12 |
AU2011257785A1 (en) | 2012-08-30 |
AU2011101749A4 (en) | 2015-02-05 |
WO2011147280A1 (zh) | 2011-12-01 |
CN101810569B (zh) | 2011-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101810569B (zh) | 一种恩诺沙星注射液及其制备方法 | |
CN102552127B (zh) | 一种奥硝唑注射液 | |
CN104323987B (zh) | 一种乙酰甲喹注射液及其制备方法 | |
CN112386572B (zh) | 一种加米霉素注射液及其制备方法 | |
CN104800167A (zh) | 一种氟苯尼考可溶性粉及其制备方法 | |
CN105454685A (zh) | 单宁微囊在制备猪用饲料添加剂中的应用 | |
CN103006554B (zh) | 一种奥硝唑注射液及其制备方法 | |
CN103126982A (zh) | 一种新兽药葡甲胺恩诺沙星注射液及其制备方法 | |
CN104856946B (zh) | 一种地塞米松磷酸钠注射液及其制备工艺 | |
CN101653448B (zh) | 兽用复方土霉素注射液及其制备方法 | |
WO2015131421A1 (zh) | 一种高硒含量硒化茶多酚制剂 | |
CN103830240A (zh) | 一种氟喹诺酮药物组合物 | |
CN105878179A (zh) | 一种氟苯尼考溶液制备方法及应用 | |
CN105012249A (zh) | 一种注射用利福平及其制备方法 | |
CN105496951A (zh) | 一种缓释恩诺沙星注射液的制备方法 | |
CN105213360B (zh) | 枸橼酸碘在制备治疗畜禽消化系统疾病的药物中的应用 | |
CN103142510A (zh) | 一种含有盐酸莫西沙星组合物的注射剂 | |
EP3733176A1 (en) | Composition comprising piperacillin, pharmaceutical preparation thereof and use thereof | |
RU2320352C2 (ru) | Способ лечения субклинического мастита у коров | |
CN105343122A (zh) | 丙酸聚六亚甲基胍畜禽鱼药物制剂 | |
CN102327365A (zh) | 用于治疗鸡大肠杆菌引起的气囊炎的口服液及制备方法 | |
CN104013951A (zh) | 一氧化氮供体型谷胱甘肽类化合物注射液及应用 | |
CN101843625B (zh) | 兽用复方氧氟沙星注射液及其制备方法 | |
CN103977028A (zh) | 甘薯叶绿原酸与纳米氧化锌抑菌组合物 | |
CN104739854B (zh) | Nac与壳聚糖复方含漱液 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enrofloxacin injection liquid and preparation method thereof Effective date of registration: 20120330 Granted publication date: 20110921 Pledgee: Bank of Dalian Co Tianjin branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2012990000114 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130415 Granted publication date: 20110921 Pledgee: Bank of Dalian Co Tianjin branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2012990000114 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enrofloxacin injection liquid and preparation method thereof Effective date of registration: 20130428 Granted publication date: 20110921 Pledgee: Bank of Dalian Co Tianjin branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2013120000007 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140708 Granted publication date: 20110921 Pledgee: Bank of Dalian Co Tianjin branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2013120000007 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Enrofloxacin injection liquid and preparation method thereof Effective date of registration: 20140724 Granted publication date: 20110921 Pledgee: China Co truction Bank Corp Tianjin Xiqing branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2014120000039 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141215 Granted publication date: 20110921 Pledgee: China Co truction Bank Corp Tianjin Xiqing branch Pledgor: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. Registration number: 2014120000039 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
ASS | Succession or assignment of patent right |
Owner name: DINGZHENG XINXING BIOTECHNOLOGY (TIANJIN) CO., LTD Free format text: FORMER OWNER: DING IS ANIMAL MEDICINE (TIANJIN) CO., LTD. Effective date: 20150320 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300402 BEICHEN, TIANJIN TO: 300000 TANGGU DISTRICT, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 300000 Taifeng Tianjin economic and Technological Development Zone, Road No. 81 building two building 201 A1 Patentee after: Ding is emerging biotechnology (Tianjin) Co., Ltd. Address before: 300402 Tianjin Road, Beichen District, Tianjin Road, Beichen science and Technology Park Road, No. 1 Patentee before: Dingzheng Animal Pharmaceutical (Tianjin) Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110921 Termination date: 20200522 |
|
CF01 | Termination of patent right due to non-payment of annual fee |